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Urachal pathologies are rare and can mimic numerous abdominal and pelvic diseases. Differential diagnosis of urachal anomalies
can be narrowed down by proper assessment of lesion location, morphology, imaging findings, patient demographics, and clinical
history. We report a case of a 60-year-old male, with a history of unintentional weight loss without associated symptoms, who
was diagnosed with locally invasive urachal adenocarcinoma. With this article, we pretend to emphasize urachal adenocarcinoma
clinical features along with its key imaging findings with radiologic-pathologic correlation.
1. Introduction
Urachal cancer (UrC) is an uncommon neoplasm, repre-
senting 0.5–2% of all bladder cancer. Although transitional
epithelium usually lines the urachus, most urachal tumors
are adenocarcinomas (90%) and represent 20%–40% of all
primary bladder adenocarcinomas [1]. Despite being such
rare entities, the number of publications regarding UrC has
increased from 3 (between 1980 and 2005) to 10 cases per year
on the last decade [2].
2. Case Presentation
We describe the case of a 60-year-old male who presented
with a four-month history of 15 kg unintentional weight loss,
without associated gastrointestinal or urogenital symptoms.
On physical examination a visible, nontender, and nonmobile
infraumbilical mass was noted.The patient denied significant
past medical or family history. Blood work showed mildly
elevated white cell count 14.4 × 109 (normal range: 4–11 × 109)
and CRP 9.1 (normal range < 0.30mg/dL).
An abdominal ultrasound was performed to determine
the mass origin. It revealed a midline mass with a central
gas-filled cavity contacting the superior bladder wall and
extending to the anterior abdominal wall (Figure 1).
Additional evaluation with contrast-enhanced abdomi-
nopelvic computed tomography (CT) confirmed the presence
of a median infraumbilical large intra-abdominal mass,
measuring 13 × 8 × 14 cm. Inferiorly it contacted the bladder
dome, and anteriorly there was infiltration of the entire thick-
ness of the anterior abdominal wall, invading the umbilicus
(Figure 2).
Posteriorly there was no fat interface between the tumor
and the transverse colon. Two fistulous tracts were perceived,
connecting the mass with this bowel segment.The remaining
study was unremarkable, with no sign of distant metastasis.
The morphology of the mass, as well as it aggressive
behavior, with abdominal wall, colon, and bladder invasion,
suggested a neoplastic lesion. Its location favored a urachal
carcinoma as the main diagnosis. Differential diagnosis
included a colon carcinomawith abdominal wall and bladder
extension, a sarcoma, and an infected urachal remnant.
A colonoscopic study was requested, but it was not com-
pleted due to fixation of a colonic loop at 30 cm. After the
procedure, discharge of fecalmaterial through skin fistulawas
noted.
Urgent laparotomy was performed, with total resection
of the tumor, with an en bloc resection of the anterior
abdominal wall, transverse colon, and superior bladder wall.
A temporary colostomy was performed.
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Figure 1: Sagittal US image of the lower abdomen obtained with a convex probe (1–6Mhz). Large mass filled with gas (star), contacting the
superior bladder wall (arrow), with focal thickening. Presence of free abdominal fluid is noted.
(a) (b)
(c) (d)
Figure 2: (a) 3D CT reconstruction showing an emaciated patient with a visible infraumbilical mass (arrow). Axial (b), coronal (c), and
sagittal (d) contrast-enhanced CT images depicting a large and heterogeneous median abdominal mass, extending from the anterosuperior
aspect of the bladder toward the umbilicus.
Specimen’s pathology revealed a poorly differentiated
adenocarcinoma with signet ring cell component and muci-
nous features. It infiltrated the skin, as well as the colonic and
bladder walls, with mucosa ulceration (Figure 3).
Immunohistochemical positivity for 34-beta-E12 and
beta-catenin (membrane) was seen (Figure 4), along with
focal positivity for CDX2 CK7, and CK20, and uroplakins
were nonreactive.
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Figure 3: Gross specimen of the tumor ((a) anterior view; (b) cross section), showing a multinodular mass with fistulization to the umbilical
skin (black arrows) and involvement of the bladder wall (red arrow) and a central necrotic cavity (star). Histologic image of the resected
tumor ((c) H&E 100x; (d) H&E 400x) showing areas with a mucinous pattern (blue star) and a signet ring cell morphology (blue arrow).
(a) (b)
Figure 4: (a) Histologic image of the resected tumor (cytokeratin 34-beta-E12, 100x). Most of the neoplastic cells expressed high molecular-
weight cytokeratins (black arrow). (b) Neoplastic cells showing diffusemembranous and cytoplasmic expression of beta-catenin (blue arrow).
Note that there is no nuclei staining (beta-catenin, 400x).
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Figure 5: Radiologic-pathologic correlation of the tumor ((a) sagittal CT image; (b) cross section of the gross specimen), showing a large
and heterogeneous mass, with thickened wall and central necrotic cavity.
This morphological and immunohistochemical fea-
tures favored the diagnosis of a urachal adenocarcinoma
(Figure 5).
The postoperative period was complicated with surgical
wound infection, and the patient was discharged from hospi-
tal after 25 days, with wound care instructions and primary
care physician referral.
3. Discussion
Theurachus is an embryological remnant that originates from
the involution of the allantois and cloaca, extending from
the umbilicus to the bladder dome. During the gestational
development, it involutes and becomes the median umbilical
ligament, with obliteration of its lumen. Most of the urachus
pathologies are found incidentally, and, with the increasing
use of cross-sectional imaging, they have become more
frequently diagnosed [3].
UrC accounts for 0.01% of all cancers in adults [1]. It was
originally described by Hue and Jacquin in 1963 and it has a
male predilection, with amean age of presentation of 60 years
(ranging from 40 to 70) [4, 5].
Symptoms do not usually accompany early UrC, which
causes patients to present at advanced stages, with local
invasion or distant metastases. The most frequently reported
symptom is hematuria, followed by abdominal pain, dysuria,
and mucosuria [2]. Less frequent clinical presentations
include other urogenital related manifestations and nonspe-
cific symptoms such as nausea, diarrhea, or weight loss. In
contrast with other bladder cancers, UrC often presents with
a palpable lower abdominal mass that along with weight loss
was the presentation in our case.
Cystoscopy remains one of the most valuable diagnostic
tools for UrC management. It allows a direct visualization of
the tumor and it can also determine if the lesion is covered
with normalmucosa, as seen in early stages, or if it is a broad-
based ulcerated mass [2].
Imaging plays also an invaluable role at UrC workup. On
Ultrasound (US), it is commonly recognized as a midline soft
tissue mass or a fluid-filled cavity with mixed echogenicity
and calcifications. CT scan is often used for local staging
and evaluation of distant metastasis. It is usually depicted as
a midline mass, superior to the bladder dome and adjacent
to the abdominal wall. In the majority of cases, the tumor
is mixed solid and cystic, the latter representing its mucin
composition. Peripheral calcifications are often seen and are
considered pathognomonic for urachal adenocarcinoma. On
MRI, focal areas of high signal in T2 indicate the presence of
mucinous component. CT andMRI are useful in demonstrat-
ing intra- or extravesical extension of the tumor.
The diagnosis of a UrC in biopsy and transurethral resec-
tion specimens remains a challenge. The criteria for patho-
logic diagnosis include the following: (1) location of the tumor
in the dome/anterior wall; (2) epicenter of carcinoma in the
bladder wall; (3) absence of widespread atypical intestinal
metaplasia and cystitis/glandularis beyond the dome/anterior
wall; (4) absence of urothelial neoplasia in the bladder; (5)
absence of a known primary tumor elsewhere [6, 7].
The most frequent histologic subtype is adenocarcinoma
with enteric features with or without mucin production.
Some have a signet ring component, as seen in our case, and
others have the morphology of colloid carcinomas [5].
Among the used immunomarkers,𝛽-catenin andCK7 are
the most important in establishing the distinction of urachal
from colorectal adenocarcinoma. Diffuse nuclear b-catenin
and CK7 help to differentiate urachal adenocarcinoma of
enteric subtype (nuclear b-catenin −, CK7 +/−), as seen in
our case, from colonic adenocarcinoma (diffuse nuclear b-
catenin +, CK7 −) [6].
The main differential diagnosis includes benign urachal
tumors, nonurachal carcinomas of the bladder, and metasta-
sis from different organs (prostate, colon, rectum, and female
genital tract). Infection of a urachal anomaly can also mimic
a UrC, and the diagnosis is often challenging at imaging. In
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our case, the presence of a midline cavity, anterosuperior to
the bladder dome, filled with low attenuation fluid, suggested
adenocarcinoma of the urachus as the main diagnosis.
Although several staging systems have been proposed for
UrC (Sheldon et al. [8], Ashley et al. [5], andPinthus et al. [9]),
their prognostic relevance has still to be validated in larger
series. It is becoming apparent that staging for UrC is more
consistent when utterly dichotomized to those confined to
urachus, bladder, and perivesical tissue (surgical specimen)
and those with spread to the peritoneum and other organs [6,
10]. Mean survival for locally advanced or metastatic disease
is 12–24 months, with a 5-year survival rate of 43% [5].
Currently, surgery is the treatment of choice for UrC.
Themost significant predictor of prognosis is surgical margin
status. Because UrC can present with metachronous or
synchronous tumors along the urachal tract, the standard
surgical approach includes excision of the urachus, umbili-
cus, and partial/radical cystectomy, combined with pelvic
lymphadenectomy [5, 8, 11].
The effective role of adjuvant or neoadjuvant chemother-
apy for UrC is not yet established [1, 12]. The fact that most
of the available data results from case reports with several
chemotherapy regimens and low case numbers does not
provide the required statistical significance. Available data
suggest that 5-fluorouracil (FU) based chemotherapies are
superior to cisplatin-based regimens regarding radiologic
tumor response, whereas the combination of 5-FU with
cisplatin provides the most beneficial response in metastatic
UrC [2, 6]. A fairly recent study described the combination
of cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy (HIPEC) to be effective in prolonging survival
in UrC patients with peritoneal metastases [13].
Abbreviations
UrC: Urachal cancer
US: Ultrasound
CT: Computed tomography
MRI: Magnetic resonance imaging
FU: Fluorouracil
HIPEC: Hyperthermic intraperitoneal chemotherapy.
Additional Points
KeyMessage. UrC is a rare malignant tumor and constitutes a
clinical challenge. Its diagnosis, management, and treatment
decisions rely on a multidisciplinary approach.
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